Brief: Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
28/08/2025 13:14
Aug 28 (Reuters) - Kyverna Therapeutics Inc KYTX.O: KYVERNA THERAPEUTICS HIGHLIGHTS NEUROIMMUNOLOGY CAR T FRANCHISE AND REGISTRATIONAL PHASE 3 TRIAL DESIGN IN MYASTHENIA GRAVIS AT VIRTUAL KOL EVENT KYVERNA THERAPEUTICS INC - KYV-101 POTENTIAL FOR DRUG-FREE REMISSION IN MG AND SPS KYVERNA THERAPEUTICS - COMPLETES PHASE 2 PORTION OF THE KYSA-6 STUDY ENROLLMENT, DATA EXPECTED Q4 Source text: ID:nGNXbbBBSs Further company coverage: KYTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyverna Therapeutics
See all newsHealth Rounds: Appendix removal linked with lower colon cancer risk in study
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
U.S. STOCKS ON THE MOVE-Everpure, Dropbox, Darden Restaurants